Center for Cancer Immune Therapy (CCIT), Department of Oncology, Copenhagen University Hospital , Herlev, Denmark.

Medicin og biovidenskab

1. Adoptive Transfer 10%
2. Antibodies 6%
3. Antigens 19%
4. Arginase 10%
5. Biomarkers 6%
6. Breast Neoplasms 7%
7. Calreticulin 10%
8. Cancer Vaccines 12%
9. Castration 6%
10. Cell- and Tissue-Based Therapy 21%
11. Chimeric Antigen Receptors 6%
12. Clinical Trials 5%
13. Clinical Trials, Phase I 5%
14. Collagen 5%
15. Cutaneous T-Cell Lymphoma 6%
16. Cytokines 7%
17. Cytotoxic T-Lymphocytes 5%
18. Dendritic Cells 34%
19. Epitopes 19%
20. Hematologic Neoplasms 5%
21. Histocompatibility Antigens Class I 6%
22. HLA Antigens 6%
23. HLA-A2 Antigen 8%
24. Immune System 9%
25. Immunity 9%
26. Immunosuppressive Agents 6%
27. Immunotherapy 41%
28. In Vitro Techniques 5%
29. Indoleamine-Pyrrole 2,3,-Dioxygenase 21%
30. Interferons 8%
31. Interleukin-2 11%
32. Ipilimumab 22%
33. Ligands 9%
34. Major Histocompatibility Complex 5%
35. Melanoma 82%
36. Monocytes 5%
37. Multiple Myeloma 5%
38. Mutation 7%
39. Natural Killer Cells 6%
40. Neoplasm Antigens 20%
41. Neoplasms 64%
42. Nivolumab 12%
43. Ovarian Neoplasms 8%
44. Pancreatic Neoplasms 5%
45. pembrolizumab 6%
46. Peptides 29%
47. Phenotype 6%
48. Polycythemia Vera 5%
49. Population 5%
50. Progression-Free Survival 6%
51. Prostatic Neoplasms 6%
52. Proteins 6%
53. Regulatory T-Lymphocytes 11%
54. Renal Cell Carcinoma 7%
55. Subunit Vaccines 11%
56. Survival 15%
57. Survivin 9%
58. T-Cell Antigen Receptor 6%
59. T-Lymphocyte Epitopes 5%
60. T-Lymphocytes 100%
61. Therapeutics 21%
62. Tissue Donors 6%
63. Tumor Microenvironment 20%
64. Tumor-Infiltrating Lymphocytes 46%
65. Vaccination 35%
66. Vaccines 20%